Clinical Pharmacokinetics

, Volume 50, Issue 4, pp 253–265

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

  • David Boulton
  • Li Li
  • Ernst U. Frevert
  • Angela Tang
  • Lorna Castaneda
  • Nimish N. Vachharajani
  • David M. Kornhauser
  • Chirag G. Patel
Original Research Article


Background and Objective

Patients with type 2 diabetes mellitus often have impaired renal function or may have impaired hepatic function, which can pose significant safety and tolerability issues for anti-hyperglycaemic pharmacotherapies. Therefore, the pharmacokinetics and tolerability of saxagliptin and its pharmacologically active metabolite, 5-hydroxy saxagliptin, in nondiabetic subjects with mild, moderate or severe renal or hepatic impairment, or end-stage renal disease (ESRD) were compared with saxagliptin and metabolite pharmacokinetics and tolerability in healthy adult subjects.


Two open-label, parallel-group, single-dose studies were conducted. Subjects received a single oral dose of saxagliptin 10 mg (Onglyza™).


Compared with healthy subjects, the geometric mean area under the plasma concentration-time curve from time zero extrapolated to infinity (AUC) for saxagliptin was 16%, 41% and 108% (2.1-fold) higher in subjects with mild, moderate or severe renal impairment, respectively. AUC values for 5-hydroxy saxagliptin were 67%, 192% (2.9-fold) and 347% (4.5-fold) higher in subjects with mild, moderate or severe renal impairment, respectively. As creatinine clearance (CLCR) values decreased, saxagliptin and 5-hydroxy saxagliptin AUC generally increased or became more variable. Twenty-three percent of the saxagliptin dose (measured as the sum of saxagliptin and 5-hydroxy saxagliptin) was cleared by haemodialysis in a 4-hour dialysis session.

In the hepatic impairment study, the differences in exposure to saxagliptin and 5-hydroxy saxagliptin were less than 2-fold across all groups. As compared with healthy subjects matched for age, bodyweight, sex and smoking status, the AUC values for saxagliptin were 10%, 38% and 77% higher in subjects with mild, moderate or severe hepatic impairment, respectively. These values were 22%, 7% and 33% lower, respectively, for 5-hydroxy saxagliptin compared with matched healthy subjects.


One-half the usual dose of saxagliptin 5mg (i.e. 2.5 mg orally once daily) is recommended for patients with moderate (CLCR 30–50 mL/min) or severe (CLCR <30 mL/min not on dialysis) renal impairment or ESRD, but no dose adjustment is recommended for those with mild renal impairment or any degree of hepatic impairment.

Supplementary material

40262_2012_50040253_MOESM1_ESM.pdf (253 kb)
Supplementary material, approximately 259 KB.


  1. 1.
    WHO. Diabetes [fact sheet no. 312; online]. Available from URL: [Accessed 2010 Dec 1]
  2. 2.
    US Renal Data System. Annual data report: 2007. Atlas of chronic kidney disease and end-stage renal disease in the United States [online]. Available from URL: [Accessed 2010 Dec 1]
  3. 3.
    Bash LD, Selvin E, Steffes M, et al. Poor glycemic control in diabetes and the risk of incident chronic kidney disease even in the absence of albuminuria and retinopathy. Arch Intern Med 2008; 168: 2440–7PubMedCrossRefGoogle Scholar
  4. 4.
    Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 2000; 32(4 Pt 1): 689–92PubMedCrossRefGoogle Scholar
  5. 5.
    El-Serag HB, Tran T, Everharts JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460–8PubMedCrossRefGoogle Scholar
  6. 6.
    Glucophage® (metformin hydrochloride): US prescribing information [online]. Available from URL: [Accessed 2010 Dec 1]
  7. 7.
    Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360–72PubMedCrossRefGoogle Scholar
  8. 8.
    Odegard PS, Setter SM, Neumiller JJ. Considerations for the pharmacological treatment of diabetes in older adults. Diabetes Spectrum 2007; 20: 239–46CrossRefGoogle Scholar
  9. 9.
    Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet 1999; 37: 399–431PubMedCrossRefGoogle Scholar
  10. 10.
    Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther 2009; 26: 249–62PubMedCrossRefGoogle Scholar
  11. 11.
    Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 376–86PubMedCrossRefGoogle Scholar
  12. 12.
    DeFronzo RA, Hissa M, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009; 32: 1649–55PubMedCrossRefGoogle Scholar
  13. 13.
    Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63: 1395–406PubMedCrossRefGoogle Scholar
  14. 14.
    Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11(6): 611–22PubMedCrossRefGoogle Scholar
  15. 15.
    Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94(12): 4810–9PubMedCrossRefGoogle Scholar
  16. 16.
    Onglyza™ (saxagliptin): US prescribing information [online]. Available from URL: [Accessed 2010 Dec 1]
  17. 17.
    De Fronzo R, Hissa MN, Garber AJ, et al. Once daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with T2D [abstract]. Diabetes 2009; 58 Suppl. 1: A147Google Scholar
  18. 18.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRefGoogle Scholar
  19. 19.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  20. 20.
    Boulton D, Goyal A, Li L, et al. The effects of age and gender on the single-dose pharmacokinetics and safety of saxagliptin in healthy subjects [abstract]. Diabetes 2008; 57 Suppl. 1: A164Google Scholar
  21. 21.
    Bristol-Myers Squibb/AstraZeneca. Saxagliptin clinical pharmacology summary. Princeton (NJ): Bristol-Myers Squibb, and Wilmington (DE): AstraZeneca, 2008(Data on file)Google Scholar
  22. 22.
    Testa R, Caglieris S, Risso D, et al. Monoethylglycinexylidide formation measurement as a hepatic function test to assess severity of chronic liver disease. Am J Gastroenterol 1997; 92: 2268–73PubMedGoogle Scholar
  23. 23.
    Uderman H. Placebo-controlled, ascending single-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of BMS-47718 in healthy subjects. Lawrenceville (NJ): Bristol-Myers Squibb, 2005(Data on file)Google Scholar
  24. 24.
    European Medicines Agency. Onglyza (saxagliptin): summary of product characteristics [online]. Available from URL: [Accessed 2010 Dec 1]
  25. 25.
    Nowicki M, Rychlik I, Haller H, et al. Saxagliptin improves glycemic control and is well tolerated in patients with type 2 diabetes mellitus (T2DM) and renal impairment compared with placebo [abstract]. Diabetes 2010; 59 Suppl. 1: A149Google Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  • David Boulton
    • 1
  • Li Li
    • 1
  • Ernst U. Frevert
    • 1
  • Angela Tang
    • 1
  • Lorna Castaneda
    • 1
  • Nimish N. Vachharajani
    • 1
  • David M. Kornhauser
    • 1
  • Chirag G. Patel
    • 1
  1. 1.Bristol-Myers SquibbPrincetonUSA
  2. 2.Discovery Medicine and Clinical PharmacologyBristol-Myers Squibb Research and DevelopmentPrincetonUSA

Personalised recommendations